

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Second Amended Accusation Against:

**SNP PHARMACY LLC doing business as
SKILLED NURSING PHARMACY;
BRENDA MANDELBAUM, BENTZION
MANDELBAUM, and MICHELLE
MANDELBAUM, Owners**

**Original Pharmacy Permit No. PHY 49974,
Sterile Compounding Permit No. LSC 99561,**

and

MINA NASR AYAD NASR

Original Pharmacist License No. RPH 78315,

Respondents.

Agency Case No. 6975

OAH No. 2021090385

MODIFIED DECISION AND ORDER

On April 25, 2022, the Board of Pharmacy adopted a Stipulated Settlement and Disciplinary Order in the above referenced case as to SNP Pharmacy LLC dba Skilled Nursing Pharmacy Only (Respondent). On May 9, 2022, the attorneys for the Respondent and the Complainant submitted a Joint Application to correct a typographical error in the Stipulated Settlement. Page 5, line 9 of Stipulated Settlement states that “during the period of probation.” In the Joint Application, counsel for both parties stated that the intent of the settlement was for a period of one year. Page 5, line 9 of the attached Stipulated Settlement and Disciplinary Order is amended to read “for a period of one year.”

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, with the correction to Page 5, line 9 as described above, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on May 25, 2022.

It is so ORDERED on May 20, 2022.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

By



Seung W. Oh, Pharm.D.
Board President

1 ROB BONTA
Attorney General of California
2 DIANN SOKOLOFF
Supervising Deputy Attorney General
3 ASPASIA A. PAPAVALASSILOU
Deputy Attorney General
4 State Bar No. 196360
1515 Clay Street, 20th Floor
5 P.O. Box 70550
Oakland, CA 94612-0550
6 Telephone: (510) 879-0818
Facsimile: (510) 622-2270
7 E-mail: Aspasia.Papavassiliou@doj.ca.gov
Attorneys for the People of the State of California

8
9 **BEFORE THE**
10 **BOARD OF PHARMACY**
11 **DEPARTMENT OF CONSUMER AFFAIRS**
12 **STATE OF CALIFORNIA**

13
14 In the Matter of the Second Amended
Accusation Against:

15 **SNP PHARMACY LLC doing business as**
16 **SKILLED NURSING PHARMACY;**
17 **BRENDA MANDELBAUM, BENTZION**
18 **MANDELBAUM, and MICHELLE**
19 **MANDELBAUM, Owners**
20 **21150 Cabot Blvd.**
21 **Hayward, CA 94545**

22 **Original Pharmacy Permit No. PHY 49974,**
23 **Sterile Compounding Permit No. LSC 99561**

24 **and**

25 **MINA NASR AYAD NASR**
26 **5045 Valley Crest Drive, #210**
27 **Concord, CA 94521**

28 **Original Pharmacist License No. RPH 78315**

Respondents.

Case No. 6975

**JOINT APPLICATION TO CORRECT
MISTAKE OR CLERICAL ERROR IN
DECISION REGARDING RESPONDENT
SNP PHARMACY LLC DBA SKILLED
NURSING PHARMACY**

1 PARTIES

2 1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy
3 (Board). She brought this action solely in her official capacity and is represented in this matter by
4 Rob Bonta, Attorney General of the State of California, by Aspasia A. Papavassiliou, Deputy
5 Attorney General.

6 2. Respondent SNP Pharmacy LLC doing business as Skilled Nursing Pharmacy
7 (Respondent) is represented in this proceeding by attorney Stacie K. Neroni of Davis, Wright,
8 Tremaine LLC, located at 865 South Figueroa Street, Suite 2400, Los Angeles, CA 90017-2566.

9 3. On or about April 25, 2022, the Board adopted as its Final Decision and Order a
10 Stipulated Settlement and Disciplinary Order for Public Repeval as to Respondent. A copy of
11 the adopted Stipulation and Disciplinary Order for Public Repeval is attached as exhibit A and
12 incorporated here by reference.

13 4. The parties, by and through their counsel, apply to correct a mistake or clerical error
14 in the Decision and Order pursuant to California Government Code section of 11518.5 subsection
15 (a), which states:

16 Within 15 days after service of a copy of the decision on a party, but not later
17 than the effective date of the decision, the party may apply to the agency for
18 correction of a mistake or clerical error in the decision, stating the specific ground on
19 which the application is made. Notice of the application shall be given to the other
parties to the proceeding. The application is not a prerequisite for seeking judicial
review.

20 5. The Stipulated Settlement and Disciplinary Order adopted and served by the Board on
21 contains a typographical or clerical error on page 5, line 9. The Stipulation erroneously stated,
22 “Within 30 days, Respondent shall retain, at its own expense, an independent consultant who
23 shall review the operations of the facility, **during the period of probation**, on a monthly basis
24 for compliance of the facility with state and federal laws and regulations governing the practice of
25 pharmacy, and compliance by respondent.” (Emphasis added to erroneous language to be
26 removed.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

6. The parties intended to have the stipulation state:

“Within 30 days, Respondent shall retain, at its own expense, an independent consultant who shall review the operations of the facility, **for a period of one year**, on a monthly basis for compliance of the facility with state and federal laws and regulations governing the practice of pharmacy, and compliance by respondent.” (Emphasis added to intended language to be added.)

APPLICATION

The parties, by and through their counsel, jointly request that the Decision and Order be corrected to state that Respondent shall retain an independent consultant for a period of one year instead of during the period of probation, with all other terms and conditions to remain the same.

DATED: _____ STACY K. NERONI
Attorney for Respondent

DATED: _____ ROB BONTA
Attorney General of California
DIANN SOKOLOFF
Supervising Deputy Attorney General

ASPASIA A. PAPAVALASSIOU
Deputy Attorney General
Attorneys for the People of the State of California

OK2020900248

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


6. The parties intended to have the stipulation state:

“Within 30 days, Respondent shall retain, at its own expense, an independent consultant who shall review the operations of the facility, **for a period of one year**, on a monthly basis for compliance of the facility with state and federal laws and regulations governing the practice of pharmacy, and compliance by respondent.” (Emphasis added to intended language to be added.)

APPLICATION


The parties, by and through their counsel, jointly request that the Decision and Order be corrected to state that Respondent shall retain an independent consultant for a period of one year instead of during the period of probation, with all other terms and conditions to remain the same.

DATED: 5-9-22


STACIE K. NERONI
Attorney for Respondent

DATED: May 9, 2022

ROB BONTA
Attorney General of California
DIANN SOKOLOFF
Supervising Deputy Attorney General


ASPASIA A. PPAVASSILIOU
Deputy Attorney General
Attorneys for the People of the State of California

OK2020900248

EXHIBIT A
Decision and Order

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Second Amended Accusation Against:

**SNP PHARMACY LLC doing business as
SKILLED NURSING PHARMACY;
BRENDA MANDELBAUM, BENTZION
MANDELBAUM, and MICHELLE
MANDELBAUM, Owners**

**Original Pharmacy Permit No. PHY 49974,
Sterile Compounding Permit No. LSC 99561,**

and

MINA NASR AYAD NASR

Original Pharmacist License No. RPH 78315,

Respondents.

Agency Case No. 6975

OAH No. 2021090385

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order for Public Repeval is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on May 25, 2022.

It is so ORDERED on April 25, 2022.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

A handwritten signature in black ink, appearing to read "Seung W. Oh". The signature is written in a cursive style with a large initial "S" and "O".

Seung W. Oh, Pharm.D.
Board President

1 ROB BONTA
Attorney General of California
2 DIANN SOKOLOFF
Supervising Deputy Attorney General
3 ASPASIA A. PAPAVALASSILOU
Deputy Attorney General
4 State Bar No. 196360
1515 Clay Street, 20th Floor
5 P.O. Box 70550
Oakland, CA 94612-0550
6 Telephone: (510) 879-0818
Facsimile: (510) 622-2270
7 E-mail: Aspasia.Papavassiliou@doj.ca.gov
Attorneys for Complainant
8

9 **BEFORE THE**
10 **BOARD OF PHARMACY**
11 **DEPARTMENT OF CONSUMER AFFAIRS**
12 **STATE OF CALIFORNIA**

13 In the Matter of the Second Accusation
Against:

14 **SNP PHARMACY LLC doing business as**
15 **SKILLED NURSING PHARMACY;**
16 **BRENDA MANDELBAUM, BENTZION**
17 **MANDELBAUM, and MICHELLE**
18 **MANDELBAUM, Owners**
19 **21150 Cabot Blvd.**
Hayward, CA 94545

20 **Original Pharmacy Permit No. PHY 49974,**
21 **Sterile Compounding Permit No. LSC 99561**

22 **and**

23 **MINA NASR AYAD NASR**
24 **5045 Valley Crest Drive, #210**
25 **Concord, CA 94521**

26 **Original Pharmacist License No. RPH 78315**

27 Respondents.

Case No. 6975

OAH No. 2021090385

**STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER FOR PUBLIC
REPROVAL REGARDING SNP
PHARMACY LLC DBA SKILLED
NURSING PHARMACY**

[Bus. & Prof. Code § 495]

28 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
entitled proceedings that the following matters are true:

1 **PARTIES**

2 1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy
3 (Board). She brought this action solely in her official capacity and is represented in this matter by
4 Rob Bonta, Attorney General of the State of California, by Aspasia A. Papavassiliou, Deputy
5 Attorney General.

6 2. Respondent SNP Pharmacy LLC doing business as Skilled Nursing Pharmacy
7 (Respondent) is represented in this proceeding by attorney Stacie K. Neroni of Davis, Wright,
8 Tremaine LLC, located at 865 South Figueroa Street, Suite 2400, Los Angeles, CA 90017-2566.

9 **JURISDICTION**

10 3. On or about December 21, 2009, the Board of Pharmacy issued Original Pharmacy
11 Permit Number PHY 49974 and Sterile Compounding Permit Number LSC 99561 to SNP
12 Pharmacy Inc., doing business as Skilled Nursing Pharmacy, with Brenda Mandelbaum as 50-
13 percent shareholder; Bentzion Mandelbaum as President and 25-percent shareholder, and
14 Michelle Mandelbaum as Director and 25-percent shareholder. On April 22, 2019, SNP
15 Pharmacy, Inc. changed its corporate name to SNP Pharmacy LLC (Respondent). The Original
16 Pharmacy Permit and Sterile Compounding Permit will expire on December 1, 2022, unless
17 renewed.

18 4. Second Amended Accusation No. 6975 was filed before the Board of Pharmacy
19 (Board), Department of Consumer Affairs and is currently pending against Respondent. The
20 Second Amended Accusation and all other statutorily required documents were properly served
21 on Respondent on or about January 24, 2022. Respondent had previously timely filed its Notice
22 of Defense contesting the Second Amended Accusation. A copy of Second Amended Accusation
23 No. 6975 is attached as exhibit A and incorporated by reference.

24 **ADVISEMENT AND WAIVERS**

25 5. Respondent has carefully read, fully discussed with counsel, and understands the
26 charges and allegations in Accusation No. 6975. Respondent has also carefully read, fully
27 discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary
28 Order for Public Repeval.

1 and agrees that they may not withdraw its agreement or seek to rescind the stipulation prior to the
2 time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its
3 Decision and Order, the Stipulated Settlement and Disciplinary Order for Public Repeval shall
4 be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action
5 between the parties, and the Board shall not be disqualified from further action by having
6 considered this matter.

7 13. The parties understand and agree that Portable Document Format (PDF) and facsimile
8 copies of this Stipulated Settlement and Disciplinary Order for Public Repeval, including PDF
9 and facsimile signatures thereto, shall have the same force and effect as the originals.

10 14. This Stipulated Settlement and Disciplinary Order for Public Repeval is intended by
11 the parties to be an integrated writing representing the complete, final, and exclusive embodiment
12 of their agreement. It supersedes any and all prior or contemporaneous agreements,
13 understandings, discussions, negotiations, and commitments (written or oral). This Stipulated
14 Settlement and Disciplinary Order for Public Repeval may not be altered, amended, modified,
15 supplemented, or otherwise changed except by a writing executed by an authorized representative
16 of each of the parties.

17 15. In consideration of the foregoing admissions and stipulations, the parties agree that
18 the Board may, without further notice or formal proceeding, issue and enter the following
19 Disciplinary Order:

20 **DISCIPLINARY ORDER**

21 IT IS HEREBY ORDERED that Original Pharmacy Permit No. PHY 49974 and Sterile
22 Compounding Permit No. LSC 99561 issued to SNP Pharmacy LLC doing business as Skilled
23 Nursing Pharmacy (Respondent) shall be publicly reprovved by the Board of Pharmacy under
24 Business and Professions Code section 495 in resolution of Accusation No. 6975, attached as
25 exhibit A.

26 **Cost Recovery**

27 Respondent shall pay \$42,075.40 to the Board for its costs associated with the investigation
28 and enforcement of this matter pursuant to Business and Professions Code Section 125.3.

1 Respondent shall be permitted to pay these costs in a payment plan approved by the board or its
2 designee, so long as full payment is completed no later than one (1) year following the effective
3 date of the decision. If Respondent fails to pay the Board costs as ordered, Respondent shall not
4 be allowed to renew its Original Pharmacy Permit and Sterile Compounding Permit until
5 Respondent pays costs in full. In addition, the Board may enforce this order for payment of its
6 costs in any appropriate court, in addition to any other rights the Board may have.

7 **Consultant Review of Pharmacy Operations**

8 Within 30 days, Respondent shall retain, at its own expense, an independent consultant who
9 shall review the operations of the facility, during the period of probation, on a monthly basis for
10 compliance of the facility with state and federal laws and regulations governing the practice of
11 pharmacy, and compliance by respondent. The consultant shall provide the board with an
12 inspection agenda for approval prior to conducting the inspection. Any inspection conducted
13 without prior approval of the inspection agenda shall not be accepted. The consultant shall also
14 provide the board with reports documenting the inspection. The reports shall be provided directly
15 to the board, and receive confirmation of receipt from the board, prior to providing to the
16 respondent. Should the board determine that the consultant is not appropriately assessing the
17 operations of respondent, or providing the appropriate written reports, the board shall require
18 respondent to obtain a different consultant through the same process outlined above, by
19 submitting a new name of an expert within sixty (60) days of respondent being notified of the
20 need for a new consultant. The board shall retain discretion to reduce the frequency of the
21 consultant's review.

22 Respondent shall submit the name of the proposed consultant for approval within thirty (30)
23 days of the effective date of this decision. The consultant shall be a pharmacist licensed by and
24 not on probation with the board or other professional as appropriate and not on probation with the
25 board, who has been approved by the board to serve in this position. The consultant shall have
26 sufficient education, training, and professional experience to be able to provide guidance to
27 respondent related to the causes for discipline in Case No. 6975. Assumption of any unauthorized
28

1 supervision responsibilities shall be considered a violation of this condition and cause for further
2 disciplinary action.

3 Failure to timely seek approval for, timely retain, or ensure timely reporting by the
4 consultant shall be considered a violation of this condition and cause for further disciplinary
5 action.

6 **Full Compliance.** As a resolution of the charges in Accusation No. 6975, this stipulated
7 settlement is contingent upon Respondent's full compliance with all conditions of this Order. If
8 Respondent fails to satisfy any of these conditions, such failure to comply constitutes cause for
9 discipline, including outright revocation, of Respondent's Original Pharmacy Permit No. PHY
10 49974 and Sterile Compounding Permit No. LSC 99561.

11 **ACCEPTANCE**

12 I have carefully read the above Stipulated Settlement and Disciplinary Order for Public
13 Repeval and have fully discussed it with our attorney Stacie K. Neroni. I understand the
14 stipulation and the effect it will have on our Original Pharmacy Permit and Sterile Compounding
15 Permit. We enter into this Stipulated Settlement and Disciplinary Order for Public Repeval
16 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
17 Board of Pharmacy.

18
19 DATED: _____

20 BREND A MANDELBAUM for
21 SNP PHARMACY LLC DBA
22 SKILLED NURSING PHARMACY;
Respondent

23 I have carefully read the above Stipulated Settlement and Disciplinary Order for Public
24 Repeval and have fully discussed it with our attorney Stacie K. Neroni. I understand the
25 stipulation and the effect it will have on our Original Pharmacy Permit and Sterile Compounding
26 Permit. We enter into this Stipulated Settlement and Disciplinary Order for Public Repeval
27

1 supervision responsibilities shall be considered a violation of this condition and cause for further
2 disciplinary action.

3 Failure to timely seek approval for, timely retain, or ensure timely reporting by the
4 consultant shall be considered a violation of this condition and cause for further disciplinary
5 action.

6 **Full Compliance.** As a resolution of the charges in Accusation No. 6975, this stipulated
7 settlement is contingent upon Respondent's full compliance with all conditions of this Order. If
8 Respondent fails to satisfy any of these conditions, such failure to comply constitutes cause for
9 discipline, including outright revocation, of Respondent's Original Pharmacy Permit No. PHY
10 49974 and Sterile Compounding Permit No. LSC 99561.

11 ACCEPTANCE

12 I have carefully read the above Stipulated Settlement and Disciplinary Order for Public
13 Repeval and have fully discussed it with our attorney Stacie K. Neroni. I understand the
14 stipulation and the effect it will have on our Original Pharmacy Permit and Sterile Compounding
15 Permit. We enter into this Stipulated Settlement and Disciplinary Order for Public Repeval
16 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
17 Board of Pharmacy.

18
19 DATED: 3-2-22

Brenda Mandelbaum
BRENDA MANDELBAUM for
SNP PHARMACY LLC DBA
SKILLED NURSING PHARMACY;
Respondent

20
21
22
23 I have carefully read the above Stipulated Settlement and Disciplinary Order for Public
24 Repeval and have fully discussed it with our attorney Stacie K. Neroni. I understand the
25 stipulation and the effect it will have on our Original Pharmacy Permit and Sterile Compounding
26 Permit. We enter into this Stipulated Settlement and Disciplinary Order for Public Repeval
27
28

1 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
2 Board of Pharmacy.

3
4 DATED: _____
5 BENTZION MANDELBAUM for
6 SNP PHARMACY LLC DBA
7 SKILLED NURSING PHARMACY;
8 *Respondent*


9 I have carefully read the above Stipulated Settlement and Disciplinary Order for Public
10 Repeval and have fully discussed it with our attorney Stacie K. Neroni. I understand the
11 stipulation and the effect it will have on our Original Pharmacy Permit and Sterile Compounding
12 Permit. We enter into this Stipulated Settlement and Disciplinary Order for Public Repeval
13 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
14 Board of Pharmacy.

15 DATED: _____
16 MICHELLE MANDELBAUM for
17 SNP PHARMACY LLC DBA
18 SKILLED NURSING PHARMACY;
19 *Respondent*


20 I have read and fully discussed with the Brenda Mandelbaum, Bentzion Mandelbaum, and
21 Michelle Mandebaum, owners of Respondent SNP Pharmacy LLC doing business as Skilled
22 Nursing Pharmacy, the terms and conditions and other matters contained in the above Stipulated
23 Settlement and Disciplinary Order for Public Repeval. I approve its form and content.

24
25 DATED: _____
26 STACIE K. NERONI
27 *Attorney for Respondent*

1 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
2 Board of Pharmacy.

3
4 DATED: 3-1-22 
5 BENTZION MANDELBAUM for
6 SNP PHARMACY LLC DBA
7 SKILLED NURSING PHARMACY;
8 Respondent

9 I have carefully read the above Stipulated Settlement and Disciplinary Order for Public
10 Reapproval and have fully discussed it with our attorney Stacie K. Neroni. I understand the
11 stipulation and the effect it will have on our Original Pharmacy Permit and Sterile Compounding
12 Permit. We enter into this Stipulated Settlement and Disciplinary Order for Public Reapproval
13 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
14 Board of Pharmacy.

15 DATED: 3-1-22 
16 MICHELLE MANDELBAUM for
17 SNP PHARMACY LLC DBA
18 SKILLED NURSING PHARMACY;
19 Respondent

20 I have read and fully discussed with the Brenda Mandelbaum, Bentzion Mandelbaum, and
21 Michelle Mandebaum, owners of Respondent SNP Pharmacy LLC doing business as Skilled
22 Nursing Pharmacy, the terms and conditions and other matters contained in the above Stipulated
23 Settlement and Disciplinary Order for Public Reapproval. I approve its form and content.

24
25 DATED: 3-2-22 
26 STACIE K. NERONI
27 Attorney for Respondent
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order for Public Repeval is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

DATED: _____

Respectfully submitted,

ROB BONTA
Attorney General of California
DIANN SOKOLOFF
Supervising Deputy Attorney General

ASPASIA A. PAPAVALASSILIOU
Deputy Attorney General
Attorneys for Complainant

OK2020900248 91470662.docx

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order for Public Repeval is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

DATED: March 3, 2022

Respectfully submitted,

ROB BONTA
Attorney General of California
DIANN SOKOLOFF
Supervising Deputy Attorney General



ASPASIA A. PAPA VASSILIOU
Deputy Attorney General
Attorneys for Complainant

OK2020900248 91470662.docx

Exhibit A

Accusation No. 6975

1 ROB BONTA
Attorney General of California
2 DIANN SOKOLOFF
Supervising Deputy Attorney General
3 ASPASIA A. PAPAVASSILIOU
Deputy Attorney General
4 State Bar No. 196360
1515 Clay Street, 20th Floor
5 P.O. Box 70550
Oakland, CA 94612-0550
6 Telephone: (510) 879-0818
Facsimile: (510) 622-2270
7 E-mail: aspasia.papavassiliou@doj.ca.gov
Attorneys for Complainant

8
9 **BEFORE THE**
10 **BOARD OF PHARMACY**
11 **DEPARTMENT OF CONSUMER AFFAIRS**
12 **STATE OF CALIFORNIA**

13 In the Matter of the Second Amended
Accusation Against:

14 **SNP PHARMACY LLC doing business as**
15 **SKILLED NURSING PHARMACY;**
16 **BRENDA MANDELBAUM, BENTZION**
17 **MANDELBAUM, and MICHELLE**
18 **MANDELBAUM, Owners**
19 **21150 Cabot Blvd.**
20 **Hayward, CA 94545**

21 **Original Pharmacy Permit No. PHY 49974,**
22 **Sterile Compounding Permit No. LSC 99561**

23 **and**

24 **MINA NASR AYAD NASR**
25 **5045 Valley Crest Drive, #210**
26 **Concord, CA 94521**

27 **Original Pharmacist License No. RPH 78315**

28 Respondents.

Case No. 6975

OAH No. 2021090385

SECOND AMENDED
ACCUSATION

PARTIES

1. Anne Sodergren (Complainant) brings this Second Amended Accusation solely in her official capacity as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

1 (4) Revoking his or her license.

2 (5) Taking any other action in relation to disciplining him or her as the board in
3 its discretion may deem proper.

4 (c) The board may refuse a license to any applicant guilty of unprofessional
5 conduct. The board may, in its sole discretion, issue a probationary license to any
6 applicant for a license who is guilty of unprofessional conduct and who has met all
7 other requirements for licensure. The board may issue the license subject to any
8 terms or conditions not contrary to public policy, including, but not limited to, the
9 following:

7 (1) Medical or psychiatric evaluation.

8 (2) Continuing medical or psychiatric treatment.

9 (3) Restriction of type or circumstances of practice.

10 (4) Continuing participation in a board-approved rehabilitation program.

11 (5) Abstention from the use of alcohol or drugs.

12 (6) Random fluid testing for alcohol or drugs.

13 (7) Compliance with laws and regulations governing the practice of pharmacy.

14 (d) The board may initiate disciplinary proceedings to revoke or suspend any
15 probationary certificate of licensure for any violation of the terms and conditions of
16 probation. Upon satisfactory completion of probation, the board shall convert the
17 probationary certificate to a regular certificate, free of conditions.

18 (e) The proceedings under this article shall be conducted in accordance with Chapter
19 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code, and
20 the board shall have all the powers granted therein. The action shall be final, except that
21 the propriety of the action is subject to review by the superior court pursuant to Section
22 1094.5 of the Code of Civil Procedure.

23 8. Section 4300.1 of the Code states:

24 The expiration, cancellation, forfeiture, or suspension of a board-issued license
25 by operation of law or by order or decision of the board or a court of law, the
26 placement of a license on a retired status, or the voluntary surrender of a license by a
27 licensee shall not deprive the board of jurisdiction to commence or proceed with any
28 investigation of, or action or disciplinary proceeding against, the licensee or to render
a decision suspending or revoking the license.

9. Section 4307, subdivision (a), of the Code states:

“Any person who has been denied a license or whose license has been revoked or is under
suspension, or who has failed to renew his or her license while it was under suspension, or who

1 has been a manager, administrator, owner, member, officer, director, associate, partner, or any
2 other person with management or control of any partnership, corporation, trust, firm, or
3 association whose application for a license has been denied or revoked, is under suspension or has
4 been placed on probation, and while acting as the manager, administrator, owner, member,
5 officer, director, associate, partner, or any other person with management or control had
6 knowledge of or knowingly participated in any conduct for which the license was denied,
7 revoked, suspended, or placed on probation, shall be prohibited from serving as a manager,
8 administrator, owner, member, officer, director, associate, partner, or in any other position with
9 management or control of a licensee as follows:

10 “(1) Where a probationary license is issued or where an existing license is placed on
11 probation, this prohibition shall remain in effect for a period not to exceed five years.

12 “(2) Where the license is denied or revoked, the prohibition shall continue until the license
13 is issued or reinstated.”

14 **STATUTORY PROVISIONS**

15 10. Section 4113, subdivision (c), of the Code, states, in pertinent part:

16 (c) The pharmacist-in-charge shall be responsible for a pharmacy’s compliance with
17 all state and federal laws and regulations pertaining to the practice of pharmacy.

18 11. Section 4126.8 of the Code states:

19 The compounding of drug preparations by a pharmacy for furnishing, distribution, or
20 use in this state shall be consistent with standards established in the pharmacy
21 compounding chapters of the current version of the United States Pharmacopeia-National
22 Formulary, including relevant testing and quality assurance. The board may adopt
23 regulations to impose additional standards for compounding drug preparations.

24 12. Section 4301 of the Code states:

25 The board shall take action against any holder of a license who is guilty of
26 unprofessional conduct or whose license has been issued by mistake. Unprofessional
27 conduct shall include, but is not limited to, any of the following:

28 . . .

(o) Violating or attempting to violate, directly or indirectly, or assisting in or
abetting the violation of or conspiring to violate any provision or term of this chapter
or of the applicable federal and state laws and regulations governing pharmacy,

1 including regulations established by the board or by any other state or federal
2 regulatory agency.

3 13. Section 4306.5 states, in pertinent part:

4 Unprofessional conduct for a pharmacist may include any of the following:

5 (a) Acts or omissions that involve, in whole or in part, the inappropriate exercise of
6 his or her education, training, or experience as a pharmacist, whether or not the act or
7 omission arises in the course of the practice of pharmacy or the ownership, management,
8 administration, or operation of a pharmacy or other entity licensed by the board.

9 (b) Acts or omissions that involve, in whole or in part, the failure to exercise or
10 implement his or her best professional judgment or corresponding responsibility with
11 regard to the dispensing or furnishing of controlled substances, dangerous drugs, or
12 dangerous devices, or with regard to the provision of services.

13 **REGULATORY PROVISIONS**

14 14. California Code of Regulations, title 16, section 1714, subdivision (b), states:

15 “Each pharmacy licensed by the board shall maintain its facilities, space, fixtures, and
16 equipment so that drugs are safely and properly prepared, maintained, secured and distributed.
17 The pharmacy shall be of sufficient size and unobstructed area to accommodate the safe practice
18 of pharmacy.”

19 15. California Code of Regulations, title 16, section 1735.2 states, in pertinent part:

20 ...

21 (e) A drug preparation shall not be compounded until the pharmacy has first prepared
22 a written master formula document that includes at least the following elements:

23 ...

24 (4) Inactive ingredients to be used.

25 (5) Specific and essential compounding steps used to prepare the drug.

26 ...

27 (g) The pharmacist performing or supervising compounding is responsible for the
28 integrity, potency, quality, and labeled strength of a compounded drug preparation until the
beyond use date indicated on the label, so long as label instructions for storage and handling
are followed after the preparation is dispensed.

1 16. California Code of Regulations, title 16, section 1735.3 states, in pertinent part:

2 (a) For each compounded drug preparation, pharmacy records shall include:

3 ...

4 (2) A compounding log consisting of a single document containing all of the
5 following:

6 ...

7 (D) The identity of the pharmacist reviewing the final drug preparation.

8 17. California Code of Regulations, title 16, section 1751.7 states, in pertinent part:

9 (b)(1) The pharmacy and each individual involved in the compounding of
10 sterile drug preparations must successfully demonstrate competency on aseptic
11 technique and aseptic area practices before being allowed to prepare sterile drug
12 preparations. The validation process shall be carried out in the same manner as
13 normal production, except that an appropriate microbiological growth medium is used
14 in place of the actual product used during sterile preparation. The validation process
15 shall be representative of the types of manipulations, products and batch sizes the
16 individual is expected to prepare and include a media-fill test. The validation process
17 shall be as complicated as the most complex manipulations performed by staff and
18 contain the same amount or greater amount of volume transferred during the
19 compounding process. The same personnel, procedures, equipment, and materials
20 must be used in the testing. Media used must have demonstrated the ability to support
21 and promote growth. Completed medium samples must be incubated in a manner
22 consistent with the manufacturer's recommendations. If microbial growth is detected,
23 then each individual's sterile preparation process must be evaluated, corrective action
24 taken and documented, and the validation process repeated.

18 ...

19 (3) The pharmacy's validation process on aseptic technique and aseptic area
20 practices must be revalidated whenever:

21 ...

22 (B) there is any change in the compounding process, the Primary Engineering
23 Control (PEC), or the compounding environment. For purposes of this subsection, a
24 change includes, but is not limited to, when the PEC is moved, repaired or replaced,
25 when the facility is modified in a manner that affects airflow or traffic patterns, or
26 when improper aseptic techniques are observed.

24 **COST RECOVERY**

25 18. Section 125.3 of the Code states, in pertinent part, that the Board may request the
26 administrative law judge to direct a licentiate found to have committed a violation or violations of
27 the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
28 enforcement of the case.

1 **DRUG DEFINITION**

2 19. Vancomycin is an antibiotic that when taken orally is used to treat bacterial intestinal
3 infections. It is designated as a dangerous drug under Business and Professions Code section
4 4022.

5 **FACTUAL ALLEGATIONS**

6 **VANCOMYCIN COMPOUNDING**

7 20. From December 1, 2018, to February 1, 2019, Respondents reconstituted vancomycin
8 5gram vials to compound at least 335 sterile compounded preparations with the incorrect amount
9 of sterile water. Moreover, the compounding logs lacked documentation of the identity of the
10 pharmacist who performed the quality review of the final product; the master formula for
11 vancomycin in sodium chloride 0.9% sterile compounds failed to include the sterile water used
12 for reconstitution of the vancomycin powder vial used in compounding; and the master formula
13 failed to include directions for reconstituting the vancomycin vial used in compounding.

14 **REFRIGERATOR TEMPERATURE**

15 21. From January 1, 2020, to October 31, 2020, Respondent SNP's refrigerator
16 temperature recordings were out of the range of the 36 to 46 degrees Fahrenheit required for the
17 proper storage of medications for 239 out of 305 days.

18 **CLEANROOM RENOVATIONS**

19 22. From April 28, 2021, the date after completion of renovations of Respondent SNP's
20 cleanroom, including replacement of the floor and work on the ante room ceiling, as well as
21 replacement of the laminar flow hood, to May 14, 2021, the date when SNP received
22 environmental sampling results, SNP compounded at least 180 sterile preparations, including at
23 least 17 total parenteral nutrition (medium risk compounds). Moreover, from April 28, 2021,
24 after the Primary Engineering Control (PEC) was replaced, to May 20, 2021, the date of the first
25 results of employee testing to validate aseptic technique in the new PEC, Respondent SNP
26 compounded at least 200 sterile preparations, of which at least 25 were total parental nutrition
27 (medium risk compounds).

28

1 **CAUSES FOR DISCIPLINE AGAINST RESPONDENT SNP**

2 **FIRST CAUSE FOR DISCIPLINE - SNP**

3 **(Incorrect Reconstitution of Compounded Drug Preparation)**

4 **(Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1735.2, subd. (g))**

5 23. Respondent SNP's Original Pharmacy Permit and Sterile Compounding Permit are
6 subject to disciplinary action because Respondent SNP compounded at least 335 vancomycin
7 sterile preparations with vancomycin 5gram vials which were reconstituted with 50mls of sterile
8 water rather than the manufacturer's FDA approved package insert instructions of 100mls of
9 sterile water. The circumstances are set forth in paragraph 20, above. (Bus. & Prof. Code, §
4301, subd. (o); Cal. Code Regs., tit. 16, § 1735.2, subd. (g).)

10 **SECOND CAUSE FOR DISCIPLINE - SNP**

11 **(Incomplete Compounding Records)**

12 **(Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1735.3, subd. (a)(2)(D))**

13 24. Respondent SNP's Original Pharmacy Permit and Sterile Compounding Permit are
14 subject to disciplinary action because Respondent SNP failed to keep complete compounding
15 records, as set forth in paragraph 20, above. (Bus. & Prof. Code, § 4301, subd. (o); Cal. Code
16 Regs., tit. 16, § 1735.3, subd. (a)(2)(D).)

17 **THIRD CAUSE FOR DISCIPLINE - SNP**

18 **(Incomplete Master Formula)**

19 **(Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1735.2,
20 subs. (e)(4) and (e)(5))**

21 25. Respondent SNP's Original Pharmacy Permit and Sterile Compounding Permit are
22 subject to disciplinary action because Respondent SNP failed to prepare a written master formula
23 document that includes inactive ingredients to be used, and specific and essential compounding
24 steps used to prepare the drug, before compounding a drug preparation, as set forth in paragraph
20, above. (Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1735.3, subs. (e)(4)
and (e)(5).)

25 **FOURTH CAUSE FOR DISCIPLINE - SNP**

26 **(Failure to Maintain Operational Standards and Security)**

27 **(Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1714, subd. (b))**

28 26. Respondent SNP's Original Pharmacy Permit and Sterile Compounding Permit are
subject to disciplinary action because Respondent SNP failed to maintain operational standards

1 and security. (Bus. & Prof. Code, §§ 4301, subd. (o), 4306.5, subds. (a) and (b); Cal. Code Regs.,
2 tit. 16, § 1714, subd. (b).) The circumstances are set forth in paragraph 21, above.

3 **FIFTH CAUSE FOR DISCIPLINE - SNP**
4 **(Compounding after Renovation without Environmental Sampling)**
5 **(Bus. & Prof. Code, §§ 4301, subd. (o), and 4126.8)**

6 27. Respondent SNP's Original Pharmacy Permit and Sterile Compounding Permit are
7 subject to disciplinary action because it engaged compounding sterile preparations after
8 compounding room renovations without waiting for environmental sampling results as required
9 by United States Pharmacopeia-National Formulary (USP), which states that environmental
10 sampling shall occur as part of a comprehensive quality management program and shall occur
11 minimally under any of the following conditions: as part of the commissioning and certification
12 of new facilities and equipment and following any servicing of facilities and equipment. (Bus. &
13 Prof. Code, §§ 4301, subd. (o), and 4126.8.) The circumstances are described in paragraph 22,
14 above

15 **SIXTH CAUSE FOR DISCIPLINE - SNP**
16 **(Compounding after PEC Change without Validation of Compounding Personnel)**
17 **(Bus. & Prof. Code, § 4301, subd. (o); Cal. Code Regs., tit. 16, § 1751.7, subd. (b)(3)(B))**

18 28. Respondent SNP's Original Pharmacy Permit and Sterile Compounding Permit are
19 subject to disciplinary action because it engaged in compounding of sterile preparations after a
20 change in the Primary Engineering Control or compounding environment without first ensuring
21 that compounding personnel demonstrated competency on aseptic technique and aseptic area
22 practices. The circumstances are described in paragraph 22, above. (Bus. & Prof. Code, § 4301,
23 subd. (o); Cal. Code Regs., tit. 16, § 1751.7, subd. (b)(3)(B).)

24 **CAUSES FOR DISCIPLINE AGAINST RESPONDENT NASR**

25 **FIRST CAUSE FOR DISCIPLINE - NASR**
26 **(Incorrect Reconstitution of Compounded Drug Preparation)**
27 **(Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o), 4306.5, subds. (a) and (b); Cal. Code**
28 **Regs., tit. 16, § 1735.2, subd. (g))**

29 29. Respondent Nasr's Original Pharmacist License is subject to disciplinary action
30 because between December 31, 2018 and February 1, 2019, while Respondent Nasr was PIC,
31 Respondent SNP compounded at least 149 vancomycin sterile preparations with vancomycin

1 5gram vials which were reconstituted with 50mls of sterile water rather than the manufacturer's
2 instructions of 100mls of sterile water. The circumstances are set forth in paragraph 20, above.
3 (Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o), 4306.5, subds. (a) and (b); Cal. Code
4 Regs., tit. 16, § 1735.2, subd. (g).)

5
6 **SECOND CAUSE FOR DISCIPLINE - NASR**
7 **(Incomplete Compounding Records)**
8 **(Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o), 4306.5, subds. (a) and (b); Cal. Code**
9 **Regs., tit. 16, § 1735.3, subd. (a)(2)(D))**

10 30. Respondent Nasr's Original Pharmacist License is subject to disciplinary action
11 because between December 31, 2018, and February 1, 2019, while Respondent Nasr was PIC,
12 Respondent SNP failed to keep complete compounding records, as set forth in paragraph 20,
13 above. (Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o), 4306.5, subds. (a) and (b); Cal.
14 Code Regs., tit. 16, § 1735.3, subd. (a)(2)(D).)

15
16 **THIRD CAUSE FOR DISCIPLINE - NASR**
17 **(Incomplete Master Formula)**
18 **(Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o), 4306.5, subds. (a) and (b); Cal. Code**
19 **Regs., tit. 16, § 1735.2, subds. (e)(4) and (e)(5))**

20 31. Respondent Nasr's Original Pharmacist License is subject to disciplinary action
21 because between December 31, 2018 and February 1, 2019, while Respondent Nasr was PIC,
22 Respondent SNP failed to prepare a written master formula document that includes inactive
23 ingredients to be used, and specific and essential compounding steps used to prepare the drug,
24 before compounding a drug preparation, as set forth in paragraph 20, above. (Bus. & Prof. Code,
25 §§ 4113, subd. (c), 4301, subd. (o), 4306.5, subds. (a) and (b); Cal. Code Regs., tit. 16, § 1735.2,
26 subds. (e)(4) and (e)(5).)

27
28 **FOURTH CAUSE FOR DISCIPLINE - NASR**
29 **(Failure to Maintain Operational Standards and Security)**
30 **(Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o), 4306.5, subds. (a) and (b); Cal. Code**
31 **Regs., tit. 16, § 1714, subd. (b))**

32 32. Respondent Nasr's Original Pharmacist License is subject to disciplinary action
33 because he failed to maintain operational standards and security while as PIC of Respondent SNP.
34 (Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o), 4306.5, subds. (a) and (b); Cal. Code

1 Regs., tit. 16, § 1714, subd. (b).) The circumstances are set forth in paragraph 21, above.

2 **FIFTH CAUSE FOR DISCIPLINE - NASR**
3 **(Compounding after Renovation without Environmental Sampling)**
4 **(Bus. & Prof. Code, §§ 4113, subd. (c), 4301, subd. (o), and 4126.8)**

5 33. Respondent Nasr's Original Pharmacist License is subject to disciplinary action
6 because as PIC of Respondent SNP he authorized compounding sterile preparations after
7 compounding room renovations without waiting for environmental sampling results as required
8 by United States Pharmacopeia-National Formulary (USP), which states that environmental
9 sampling shall occur as part of a comprehensive quality management program and shall occur
10 minimally under any of the following conditions: as part of the commissioning and certification
11 of new facilities and equipment and following any servicing of facilities and equipment. (Bus. &
12 Prof. Code, §§ 4113, subd. (c), 4301, subd. (o), and 4126.8.) The circumstances are described in
13 paragraph 22, above.

14 **SIXTH CAUSE FOR DISCIPLINE - NASR**
15 **(Compounding after PEC Change without Validation of Compounding Personnel)**
16 **(Bus. & Prof. Code, §§ 4113, subd. (c), and 4301, subd. (o); Cal. Code Regs., tit. 16, § 1751.7,**
17 **subd. (b)(3)(B))**

18 34. Respondent Nasr's Original Pharmacist License is subject to disciplinary action
19 because as PIC of Respondent PIC he authorized compounding of sterile preparations after a
20 change in the Primary Engineering Control or compounding environment without first ensuring
21 that compounding personnel demonstrated competency on aseptic technique and aseptic area
22 practices. The circumstances are described in paragraph 22, above. (Bus. & Prof. Code, §§ 4113,
23 subd. (c), 4301, subd. (o); Cal. Code Regs., tit. 16, § 1751.7, subd. (b)(3)(B).)

24 **DISCIPLINE CONSIDERATIONS**

25 To determine the degree of discipline to be imposed on Respondents, Complainant
26 further alleges that the Board issued Respondents the below-listed citations, which are now final.

27 **RESPONDENT SNP ONLY**

28 35. On or about August 16, 2017, Respondent SNP was issued Citation No. CI 2017
75997 for its pharmacy permit and Citation No. CI 2016 7286 for its sterile compounding permit
for the following violations, discovered during an inspection on or about November 2, 2016:

- 1 • The annual review of compounding policies and procedures had not been documented
2 as reviewed by the Pharmacist in Charge, in violation of California Code of
3 Regulations, title 16, section 1735.5, subdivision (b);
- 4 • The weekly cleaning of the walls, ceilings, floors, shelves, tables and stools had not
5 been documented from March 2016 to October 2016, in violation of California Code
6 of Regulations, title 16, section 1751.4(d);
- 7 • The refrigerator temperatures were outside the stated acceptable temperature range
8 approximately 38 times between March 2016 and October 2016, in violation of
9 California Code of Regulations, title, section 1714, subdivision (b);
- 10 • Prescription number 7235121 failed to list the inactive ingredient and amount used to
11 reconstitute the active ingredient, in violation of the California Code of Regulations,
12 title 16, section 1735.3(a)(5); and
- 13 • Prescription number 7235121 failed to list the inactive ingredient manufacturer, lot
14 number and expiration date used to reconstitute the active ingredient, in violation of
15 California Code of Regulations, title 16, section 1735.3(a)(6).

16 36. On or about May 14, 2020, Respondent SNP was issued Citation No. CI 2018 82624
17 regarding its pharmacy permit for failing to review a patient's drug therapy and medication
18 record, in violation of California Code of Regulations, title 16, section 1707.3, and for failing to
19 verify an uncertain or erroneous prescription, in violation of California Code of Regulations, title
20 16, section 1761. Specifically, on July 11, 2018, SNP pharmacist CN failed to screen for severe
21 potential drug therapy problems while reviewing RX# 7958076 and dispensing the prescription to
22 ME without contacting the prescriber to validate the uncertain direction of daily dosing of
23 methotrexate for the treatment of rheumatoid arthritis; and on July 24, 2018, SNP pharmacist AD
24 failed to screen for severe potential drug therapy problems while reviewing RX# 7973015 and
25 dispensing the prescription to ME without contacting the prescriber to validate the uncertain
26 direction of daily dosing of methotrexate for the treatment of rheumatoid arthritis. ME was
27 dispensed methotrexate 2.5 mg with directions to take one tablet daily instead of four tablets
28 weekly, and subsequently suffered from methotrexate toxicity, ultimately resulting in patient

1 death. Additionally, RX# 7958076 and RX# 7973015 were dispensed pursuant to faxed discharge
2 instructions, and not a valid chart order or telephone order from the facility. Furthermore, the
3 dispensing pharmacist failed to contact the prescriber to obtain an oral order or to verify the
4 uncertain order prior to dispensing the prescription.

5 **RESPONDENTS SNP AND NASR**

6 37. On or about May 21, 2020, Respondent SNP was issued Citation No. CI 2019 87894
7 for its pharmacy permit and Citation No. CI 2019 86128 its sterile compounding permit, and
8 Respondent Nasr was issued Citation No. CI 2019 87893. The basis for the citations was that on
9 or about October 30, 2019, Respondents failed to ensure that all equipment used in the designated
10 area or cleanroom was made of a material that could be easily cleaned and disinfected (Cal. Code
11 Regs., tit. 16, § 1751.4, subds. (c) and (e)); and Respondents failed to ensure adequate training of
12 sterile injectable compounding staff (Cal. Code Regs., tit. 16, § 1751.6, subd. (e)(1)).
13 Specifically, a technician failed to properly demonstrate the cleaning of the laminar air flow
14 workbench (LAFW) and did not know the cleaning agents required and their dwell times for use.
15 In addition, the technician failed to clean the ceiling and back wall of the LAFW and there was no
16 ceiling panel covering the light fixture allowing staff to clean the ceiling. Furthermore, the
17 pharmacy also had a hole in the ceiling making the ISO 7 buffer room exposed to outside air and
18 a rolling stool with a plastic bag covering the seat making these areas not cleanable surfaces.
19 Finally, the pharmacy failed to have complete training records for all their compounding staff.

20 **OTHER MATTERS**

21 38. Pursuant to section 4307 of the Code, if discipline is imposed on Original Pharmacy
22 Permit Number PHY 49974, issued to SNP Pharmacy LLC., doing business as Skilled Nursing
23 Pharmacy with Brenda Mandelbaum as 50-percent shareholder, Bentzion Mandelbaum as
24 President and 25-percent shareholder, and Michelle Mandelbaum as Director and 25-percent
25 shareholder, while Brenda Mandelbaum, Bentzion Mandelbaum, and Michelle Mandelbaum were
26 shareholders of Skilled Nursing Pharmacy and had knowledge of or knowingly participated in
27 any conduct for which Original Pharmacy Permit Number PHY 49974 was disciplined, Brenda
28 Mandelbaum, Bentzion Mandelbaum, and Michelle Mandelbaum shall be prohibited from serving

1 as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee
2 for five years if Original Pharmacy Permit Number PHY 49974 is placed on probation or until
3 Original Permit Number PHY 49974 is reinstated if it is revoked.

4 **PRAYER**

5 WHEREFORE, Complainant requests that a hearing be held on the matters here alleged,
6 and that following the hearing, the Board of Pharmacy issue a decision:

- 7 1. Revoking or suspending Original Pharmacy Permit Number PHY 49974, issued to
8 SNP Pharmacy LLC doing business as Skilled Nursing Pharmacy;
- 9 2. Revoking or suspending Sterile Compounding Permit Number LSC 99561, issued to
10 SNP Pharmacy LLC doing business as Skilled Nursing Pharmacy;
- 11 3. Revoking or suspending Original Pharmacist License Number RPH 78315, issued to
12 Mina Nasr Ayad Nasr;
- 13 4. Prohibiting Brenda Mandelbaum, Bentzion Mandelbaum, and Michelle Mandelbaum
14 from serving as a manager, administrator, owner, member, officer, director, associate, or partner
15 of a licensee for five years if Original Pharmacy Permit Number PHY 49974 is placed on
16 probation or until Original Pharmacy Permit Number PHY 49974 is reinstated if Original
17 Pharmacy Permit Number 49974 issued to SNP Pharmacy LLC doing business as Skilled Nursing
18 Pharmacy, is revoked;
- 19 5. Ordering SNP Pharmacy LLC and Mina Nasr Ayad Nasr to pay the Board of
20 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to
21 Business and Professions Code section 125.3; and,
- 22 6. Taking such other and further action as deemed necessary and proper.

23
24 DATED: 1/24/2022

Signature on File

25 ANNE SODERGREN
26 Executive Officer
27 Board of Pharmacy
28 Department of Consumer Affairs
State of California
Complainant

OK2020900248 91440354.docx